Conference webcast, page-2

Hi Jessie,

It is good to see you here again.

Next quarter royalty revenue from Relenza and Inavir should be around 1.5 times of that of last quarter, namely, $6.5m x 1.5 = $9.7 m . Hopefully, the sales milestone payment has been triggered again so that Biota can receive extra several $m in addition to the royalty.

We all have lost a lot on this stock including the missed opportunities on ASX.  PC's smiling facing is still haunting in my mind. Biota Joke

Good luck to all Biota shareholders.